Company intelligence / Profile preview
SCOLR Pharma
Bothell, Washington, USAscolr.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
SCOLR Pharma developed a proprietary controlled-release oral drug delivery platform used in both prescription and over-the-counter products. Its lead candidate was a 12-hour extended-release ibuprofen that completed Phase III trials. Several nutritional supplement formulations using the CDT platform were commercialized through partnerships with Perrigo. The company was acquired by Probi USA in October 2016 and is no longer independently active.
- Therapeutic areas
- GastroenterologyPulmonologyCardiovascularPsychiatryImmunologyEndocrinologyOtherWomen's HealthNeurology
- Modalities
- Small moleculeNutritional productDevice
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Perrigo Company of South Carolina—manufacture/distribution of dietary supplements using CDT technology
Beyond the preview
Go deeper on SCOLR Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCOLR Pharma.